-
Mashup Score: 2BOVen Regimen NCCN-Approved Option for TP53-Mutated MCL | ASH Clinical News | American Society of Hematology - 9 hour(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. The three-drug regimen of zanubrutinib, obinutuzumab, and venetoclax—dubbed the BOVen regimen—is an effective option for patients with TP53 -mutated mantle cell lymphoma (MCL), according to results of a phase II study published in Blood. 1 This “chemo-free” regimen combining a BTK inhibitor, BCL2 inhibitor, and an anti-CD20 monoclonal antibody yielded a high overall response rate (ORR), high rates of complete response (CR), and a
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Many phase III cancer clinical trials exclude individuals with absolute neutrophil counts (ANCs) within the reference range for individuals with the Duffy null–associated ANC (DANC) phenotype. Many individuals with DANC are of African and Middle Eastern ancestry, and current clinical trials exclude some of these participants because of these predefined criteria. Individuals with DANC may also be receiving modified
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Recent findings show that many phase III #cancer clinical trials exclude individuals with absolute #neutrophil counts that are within the reference range for those with the Duffy null phenotype, with 76.5% of trials observed having such exclusion criteria: https://t.co/wBTZI6K9Hx
-
-
Mashup Score: 5
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. Historically, hematologists have feared Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) because of its poor prognosis. However, new research suggests that dual BCR::ABL1 kinase inhibition with dasatinib and asciminib is a safe treatment for patients with de novo Ph+ ALL. Marlise Luskin, MD, MSCE, of Dana-Farber Cancer Institute in Boston, and colleagues published their findings in Blood. “This is a rare
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
According to research published in @BloodJournal, combination treatment with #asciminib and #dasatinib was efficacious in Ph+ #AcuteLymphoblasticLeukemia (ALL), with all patients on study with de novo ALL achieving hematologic and cytogenetic remission: https://t.co/gT5vqdXwhk
-
-
Mashup Score: 0MRD-Guided Therapy Improves Quality of Life for Patients With CLL | ASH Clinical News | American Society of Hematology - 14 day(s) ago
Anna Azvolinsky is a science and health journalist based in New York City. Time-limited treatment with ibrutinib plus venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) guided by measurable residual disease (MRD) significantly improves quality of life (QoL) for these patients, including mitigating fatigue. 1 The patients saw clinically relevant improvements after one year at the end of their combination therapy course, including a 9-point improvement in global
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Time-limited, MRD-guided treatment with #ibrutinib plus #venetoclax in patients with R/R #ChronicLymphocyticLeukemia led to significant improvements in quality of life for these patients, including mitigating fatigue: https://t.co/8DFWWIW3Y5 #ASH24
-
-
Mashup Score: 0
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Anemia and hypertension were the two modifiable risk factors most closely related to anticoagulant-associated bleeding risk in patients with cancer, according to findings from a large database analysis that will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The study suggests that eliminating these and other risk factors that are within the patient’s control could substantially
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
#Anemia and #hypertension were the modifiable risk factors most closely related to #anticoagulant-associated #bleeding risk in patients with #cancer, and the elimination of both brought a ~19% reduction in the probability of bleeding after one year: https://t.co/CxIqPrzZmN #ASH24
-
-
Mashup Score: 3Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL | ASH Clinical News | American Society of Hematology - 15 day(s) ago
Anna Azvolinsky is a science and health journalist based in New York City. Patients with heavily pretreated, relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab, a bispecific antibody, had a high overall response rate (ORR) and complete response (CR) rate, as well as a high rate of undetectable measurable residual disease (uMRD). The therapy also had an acceptable side effect profile. These results, from the phase 1b/2 EPCORE CLL-1 trial, will be presented at the 66th
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
#ASH24 Among patients with heavily pretreated, R/R #ChronicLymphocyticLeukemia, treatment with the #bispecific antibody #epcoritamab led to high rates of overall and complete response, as well as a high rate of uMRD: https://t.co/KqcW7S885g
-
-
Mashup Score: 2Considerable Morbidity and Mortality Seen in AIHA, Long-Term Study Finds | ASH Clinical News | American Society of Hematology - 15 day(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. In a long-term look at the clinical features and course of disease for children with autoimmune hemolytic anemia (AIHA), patients were found to have considerable morbidity and mortality rates. Researchers will discuss the findings at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. AIHA is a rare pediatric disease for which there is little guidance for evaluation and treatment and poor understanding
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
#ASH24 In a long-term look at children with #AIHA, patients were found to have considerable morbidity and mortality rates, with high rates of secondary AIHA (~30%), #EvansSyndrome (37%), and chronic or relapsing course of disease (34%): https://t.co/H7wGktf8ta
-
-
Mashup Score: 2CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds | ASH Clinical News | American Society of Hematology - 16 day(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy who achieved a complete response (CR) after a year went on to have good long-term overall survival (OS) and progression-free survival (PFS), according to findings that will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The data suggest,
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet-
Patients with R/R #ChronicLymphocyticLeukemia treated with anti-CD19 chimeric CAR #TcellRX who achieved a PR or better after a year went on to have strong long-term OS and PFS, with respective five-year rates of 78.6% and 57.1%: https://t.co/iQZYJw2Bi7 #ASH24
-
-
Mashup Score: 3
Khylia Marshall is a freelance journalist based in Tucson, Arizona. On Sunday, December 8 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, Jordan K. Schaefer, MD, MSc, of the University of Michigan in Ann Arbor, will present findings that support the 2021 American College of Chest Physician Guidelines for reduced-dose apixaban or rivaroxaban in secondary prevention of venous thromboembolism (VTE). The registry-based cohort study showed reduced direct oral anticoagulant
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
According to findings to be presented at #ASH24, reduced #DOAC dosing was found to be associated with a decreased #bleeding rate and lower #healthcare utilization in the setting of secondary prevention of #VTE: https://t.co/IvNzrhf0Gz
-
-
Mashup Score: 7
Khylia Marshall is a freelance journalist based in Tucson, Arizona. At a December 8 plenary session of the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, Rachel Rau, MD, associate professor of pediatrics at Seattle Children’s Hospital in Washington, will present on the addition of blinatumomab as a new standard treatment for children with both average- and higher-risk newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). In the phase III randomized Children’s Oncology
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Compared with #chemotherapy alone, the addition of #blinatumomab to standard intensity chemotherapy resulted in significantly superior DFS among children with both average- and higher-risk newly diagnosed B-cell #AcuteLymphoblasticLeukemia: https://t.co/Sn99LbbFlu #ASH24
-
The three-drug regimen of #zanubrutinib, #obinutuzumab, and #venetoclax was found to be an effective option for patients with TP53-mutated #MantleCellLymphoma, with an ORR of 96% and CR of 88%: https://t.co/Sbdp8HsDv7